GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTY) » Definitions » Cash Flow from Financing

RLFTY (Relief Therapeutics Holding) Cash Flow from Financing : $-0.83 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Relief Therapeutics Holding Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2024, Relief Therapeutics Holding paid $0.00 Mil more to buy back shares than it received from issuing new shares. It spent $0.69 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Relief Therapeutics Holding spent $0.69 Mil on financial activities for the six months ended in Jun. 2024.


Relief Therapeutics Holding Cash Flow from Financing Historical Data

The historical data trend for Relief Therapeutics Holding's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Cash Flow from Financing Chart

Relief Therapeutics Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 65.51 73.50 6.89 4.68

Relief Therapeutics Holding Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.81 1.88 4.64 -0.14 -0.69

Relief Therapeutics Holding Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Relief Therapeutics Holding's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Relief Therapeutics Holding's Cash from Financing for the quarter that ended in Jun. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relief Therapeutics Holding  (OTCPK:RLFTY) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Relief Therapeutics Holding's issuance of stock for the six months ended in Jun. 2024 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Relief Therapeutics Holding's repurchase of stock for the six months ended in Jun. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Relief Therapeutics Holding's net issuance of debt for the six months ended in Jun. 2024 was $-0.69 Mil. Relief Therapeutics Holding spent $0.69 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Relief Therapeutics Holding's net issuance of preferred for the six months ended in Jun. 2024 was $0.00 Mil. Relief Therapeutics Holding paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Relief Therapeutics Holding's cash flow for dividends for the six months ended in Jun. 2024 was $0.00 Mil. Relief Therapeutics Holding received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Relief Therapeutics Holding's other financing for the six months ended in Jun. 2024 was $0.00 Mil. Relief Therapeutics Holding received $0.00 Mil on other financial activities.


Relief Therapeutics Holding Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.